Fabrication of mesoporous hydroxycarbonate apatite for oral delivery of poorly water-soluble drug carvedilol
Source abstract
Abstract
Abstract The main aim of this study was to prepare nanosized hydroxycarbonate apatite (HCA) as a drug carrier to improve the dissolution rate and increase the bioavailability of poorly soluble drugs, intended to be administered orally. In the present study, uniform mesoporous HCA nanoparticles were synthesized using CaCO3 as a sacrificial template by the hydrothermal method in the presence of cetyltrimethylammonium bromide (CTAB) as a surfactant. The prepared HCA was used as a drug carrier to investigate the drug uptake and release properties employing carvedilol (CAR) as a model drug. The structure and morphology of mesoporous HCA, and the successful storage/release of CAR were systematically studied by N2 adsorption, scanning electron microscopy (SEM), powder X-Ray diffraction (XRD), differential scanning calorimetry (DSC), thermogravimetric (TG) analysis, Fourier transform infrared (FT-IR) spectroscopy, and UV–VIS spectrophotometry. In vitro drug dissolution tests showed that mesoporous HCA produced burst release of CAR in comparison with micronized CAR in simulated gastric fluid and intestinal fluid. Stability test result indicated that amorphous state of CAR loaded in HCA nanoparticles had a good physical stability after room storage for 6 months. Hence, mesoporous HCA nanoparticles are excellent drug carriers for the oral delivery of poorly soluble drugs.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Crystallization and Solubility Studies · Calcium Carbonate Crystallization and Inhibition
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. Nanosizing— oral formulation development and biopharmaceutical evaluation10.1016/j.addr.2007.05.003 ↗
2. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections10.1016/j.addr.2007.08.042 ↗
3. Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs10.1016/j.ijpharm.2010.09.040 ↗
4. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting10.1016/S0169-409X(00)00129-0 ↗
5. Poor aqueous solubility — an industry wide problem in drug discovery
6. Improving drug solubility for oral delivery using solid dispersions10.1016/S0939-6411(00)00076-X ↗
7. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs10.1016/j.drudis.2007.09.005 ↗
8. Inclusion complexes of tadalafil with natural and chemically modified b-cyclodextrins I: preparation and in vitro evaluation10.1016/j.ejpb.2008.06.024 ↗
9. Nanosizing: a formulation approach for poorly-water-soluble compounds10.1016/S0928-0987(02)00251-8 ↗
10. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization10.1016/j.ejpb.2005.05.009 ↗
11. Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability10.1016/j.ijpharm.2004.07.010 ↗
12. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs10.1016/j.jconrel.2005.09.051 ↗
13. Well-ordered mesoporous bioactive glasses (MBG): a promising bioactive drug delivery system10.1016/j.jconrel.2005.11.002 ↗
14. Polymeric micelle-templated synthesis of hydroxyapatite hollow nanoparticles for a drug delivery system10.1016/j.actbio.2009.12.014 ↗
15. Self-activated luminescent and mesoporous strontium hydroxyapatite nanorods for drug delivery10.1016/j.biomaterials.2010.01.044 ↗
16. Self-assembled ceramics produced by complex-fluid templation10.1146/annurev.physchem.51.1.601 ↗
17. Biological and medical significance of calcium phosphates10.1002/1521-3773(20020902)41:17<3130::AID-ANIE3130>3.0.CO;2-1 ↗
18. Development, characterization and stabilization of amorphous form of a low Tg drug10.1016/j.powtec.2006.05.012 ↗
19. Fabrication and characterization of hydroxycarbonate apatite with mesoporous structure10.1016/j.micromeso.2008.09.024 ↗
20. Fast precipitation of uniform CaCO3 nanospheres and their transformation to hollow hydroxyapatite nanospheres10.1016/j.jcis.2010.08.060 ↗
21. Inclusion of telmisartan in mesocellular foam nanoparticles: drug loading and release property10.1016/j.ejpb.2010.05.010 ↗
22. Synthesis of ultra-large-pore SBA-15 silica with two-dimensional hexagonal structure using triisopropylbenzene as micelle expander10.1021/cm8012733 ↗
23. Mesocellular siliceous foams with uniformly sized cells and windows10.1021/ja983218i ↗
24. Direct synthesis and characterization of highly ordered functional mesoporous silica thin films with high amino-groups content10.1016/j.apsusc.2007.10.022 ↗
25. Size-controlled synthesis of monodispersed mesoporous silica nano-spheres under a neutral condition10.1016/j.micromeso.2008.08.004 ↗
26. Preparation of hollow mesoporous silica spheres by a sol–gel/emulsion approach10.1016/j.micromeso.2009.06.028 ↗
27. Mesoporous silicon microparticles for oral drug delivery: loading and release five model drugs10.1016/j.jconrel.2005.08.017 ↗
28. Selective in vitro effect of peptides on calcium carbonate crystallization10.1021/cg0255467 ↗
29. Fluoridated hydroxyapatite solubility and caries formation10.1038/247064a0 ↗
30. Nucleation of calcium carbonate in presence of citric acid, DTPA, EDTA and pyromellitic acid10.1016/j.jcis.2004.09.071 ↗
31. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug10.1016/j.jcis.2011.07.022 ↗
32. What is the true solubility advantage for amorphous harmaceuticals?10.1023/A:1007516718048 ↗